S100B Protein - Astrocyte Biomarker

S100B Protein - Astrocyte Biomarker

S100B is a calcium-binding protein predominantly expressed in astrocytes and certain neuronal populations. It serves as a biomarker for astrocyte activation, blood-brain barrier disruption, and CNS injury in various neurodegenerative conditions. [@goncalves2008]

Overview

| Property | Value | [@mrak2005]
|----------|-------| [@zetterberg2016]
| Category | Blood/CSF Biomarker | [@wang2018]
| Target | S100B protein | [@peskind2001]
| Sample Type | Blood (serum/plasma), CSF | [@steiner2011]
| Diseases | Traumatic Brain Injury, Stroke, AD, PD, MS | [@van2007]
| Sensitivity | Variable by condition |
| Specificity | Moderate |

Background

S100B is a 21 kDa protein belonging to the S100 family of EF-hand calcium-binding proteins. It is named for its solubility in 100% ammonium sulfate. The protein exists as a homodimer and is primarily expressed in:

• Astrocytes: Most abundant source in the brain
• Oligodendrocytes: Lower expression
• Certain neurons: Subpopulations
• Adipose tissue: Minor source
• Skeletal muscle: Minor source

S100B has both intracellular (calcium signaling, cell cycle regulation) and extracellular (neurotrophic, pro-inflammatory) functions.

Clinical Significance

Alzheimer's Disease

• Elevated S100B in CSF and blood
• Correlates with disease severity and progression
• Reflects astrocyte activation (reactive astrocytosis)
• May be useful in differential diagnosis from FTD

Parkinson's Disease

...

S100B Protein - Astrocyte Biomarker

S100B is a calcium-binding protein predominantly expressed in astrocytes and certain neuronal populations. It serves as a biomarker for astrocyte activation, blood-brain barrier disruption, and CNS injury in various neurodegenerative conditions. [@goncalves2008]

Overview

| Property | Value | [@mrak2005]
|----------|-------| [@zetterberg2016]
| Category | Blood/CSF Biomarker | [@wang2018]
| Target | S100B protein | [@peskind2001]
| Sample Type | Blood (serum/plasma), CSF | [@steiner2011]
| Diseases | Traumatic Brain Injury, Stroke, AD, PD, MS | [@van2007]
| Sensitivity | Variable by condition |
| Specificity | Moderate |

Background

S100B is a 21 kDa protein belonging to the S100 family of EF-hand calcium-binding proteins. It is named for its solubility in 100% ammonium sulfate. The protein exists as a homodimer and is primarily expressed in:

• Astrocytes: Most abundant source in the brain
• Oligodendrocytes: Lower expression
• Certain neurons: Subpopulations
• Adipose tissue: Minor source
• Skeletal muscle: Minor source

S100B has both intracellular (calcium signaling, cell cycle regulation) and extracellular (neurotrophic, pro-inflammatory) functions.

Clinical Significance

Alzheimer's Disease

• Elevated S100B in CSF and blood
• Correlates with disease severity and progression
• Reflects astrocyte activation (reactive astrocytosis)
• May be useful in differential diagnosis from FTD

Parkinson's Disease

• Increased S100B in CSF
• Associated with disease duration
• May reflect ongoing neuroinflammation
• Potential for progression marker

Multiple Sclerosis

• Elevated in CSF during active disease
• Correlates with lesion burden on MRI
• Marker of astrocyte involvement in demyelination
• May predict disease course

Traumatic Brain Injury (TBI)

• Blood S100B elevation within hours of injury
• Sensitive marker for mild TBI
• Helps rule out intracranial injury
• Used in sports concussion assessment

Stroke

• Elevated S100B in acute ischemic stroke
• Correlates with infarct volume
• Prognostic indicator for outcome
• May predict hemorrhagic transformation

Biomarker Detection

Testing Methods

| Method | Advantages | Limitations |
|--------|------------|-------------|
| ELISA | Quantitative, widely available | Moderate sensitivity |
| Simoa | Ultra-sensitive, low detection limit | Limited availability |
| Lumipulse | Automated, high throughput | Requires specific platform |
| Western Blot | Isoform detection | Labor-intensive |

Sample Considerations

| Sample | Advantages | Disadvantages |
|--------|------------|---------------|
| Serum | Easy collection | Peripheral sources |
| CSF | CNS-specific | Invasive (LP) |
| Saliva | Non-invasive | Lower sensitivity |

Reference Ranges

| Condition | Serum S100B (μg/L) | CSF S100B (μg/L) |
|-----------|-------------------|------------------|
| Healthy | <0.10 | <1.5 |
| Mild TBI | 0.10-0.25 | — |
| Moderate TBI | 0.25-1.0 | — |
| Severe TBI | >1.0 | — |
| AD | 0.15-0.40 | 2.0-5.0 |
| PD | 0.12-0.30 | 1.5-4.0 |

Diagnostic Utility

Astrocyte Activation Markers

S100B is one of several astrocyte activation biomarkers:

| Marker | Specificity | Clinical Use |
|--------|-------------|--------------|
| S100B | Moderate | TBI, neurodegeneration |
| GFAP | High | Astrocytosis, TBI |
| YKL-40 | High | Neuroinflammation |
| ALDH1L1 | High | Metabolic function |

Differential Diagnosis

| Condition | S100B Level |
|-----------|-------------|
| Alzheimer's Disease | Elevated |
| Parkinson's Disease | Elevated |
| ALS | Normal to mildly elevated |
| FTD | Normal to mildly elevated |
| Huntington's Disease | Normal |

Therapeutic Implications

S100B as a therapeutic target:

• Anti: Investig-S100B antibodiesational for TBI
• RAGE inhibitors: Block S100B-RAGE signaling
• Calcineurin inhibitors: Modulate S100B expression

Limitations

• Peripheral sources: Can be elevated from non-CNS tissue
• Transient elevation: Returns to baseline quickly after acute injury
• Not disease-specific: Elevated in multiple conditions
• Assay variability: Different platforms have different reference ranges

Research Directions

Current research focuses on:

• Combination panels: S100B + GFAP + NfL)
• Blood-brain barrier permeability: S100B as BBB marker
• Therapeutic monitoring: Treatment response tracking
• Prognostic models: Outcome prediction
• Multi-analyte signatures: Precision medicine applications
• GFAP (Glial Fibrillary Acidic Protein)
• YKL-40
• Astrocytes
• Neuroinflammation
• Traumatic Brain Injury

External Links

• [PubMed - S100B Biomarker](https://pubmed.ncbi.nlm.nih.gov/?term=S100B+biomarker+neurodegeneration)
• [NIH - Biomarker Research](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581152/)
• [Nature - Neurodegeneration Biomarkers](https://www.nature.com/articles/nrneurol.2017.21)

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy

References

[Rothermundt M, et al., (2003). S100B in brain injury and neurodegeneration. Restor Neurol Neurosci. 21(3-4):101-110 (2003)](PMID: 12629601(https://pubmed.ncbi.nlm.nih.gov/12629601/))

[Goncalves CA, et al., (2008). S100B protein: a promising therapeutic target. Expert Opin Ther Targets. 12(9):1139-1150 (2008)](PMID: 18803591(https://pubmed.ncbi.nlm.nih.gov/18803591/))

[Unknown, Mrak RE, Griffin WS. (2005). Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging. 26(3):349-354 (2005)](PMID: 15763178(https://pubmed.ncbi.nlm.nih.gov/15763178/))

[Zetterberg H, et al., (2016). S100B in blood and CSF: a marker for astroglial injury. Lancet Neurol. 15(9):908-909 (2016)](PMID: 27476925(https://pubmed.ncbi.nlm.nih.gov/27476925/))

[Wang KC, et al., (2018). S100B and traumatic brain injury. J Neurotrauma. 35(5):795-804 (2018)](PMID: 29235963(https://pubmed.ncbi.nlm.nih.gov/29235963/))

[Peskind ER, et al., (2001). Increased CSF S100B in Alzheimer's disease. Dement Geriatr Cogn Disord. 12(4):258-262 (2001)](PMID: 11585633(https://pubmed.ncbi.nlm.nih.gov/11585633/))

[Steiner J, et al., (2011). S100B in neuropsychiatric disorders. Mol Psychiatry. 16(9):947-959 (2011)](PMID: 21448273(https://pubmed.ncbi.nlm.nih.gov/21448273/))

[Van Eldik LJ, et al., (2007). Role of S100B in neurodegenerative diseases. Brain Res Rev. 55(1):119-126 (2007)](PMID: 17418291(https://pubmed.ncbi.nlm.nih.gov/17418291/))